Assembly Biosciences (ASMB) Operating Income (2010 - 2026)

Assembly Biosciences' Operating Income history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.

• In Q1 2026, Operating Income fell 14.37% year-over-year to -$11.4 million; the TTM figure through Mar 2026 stood at -$2.7 million (up 93.92% YoY), while the FY2025 annual figure was -$1.3 million, up 97.17% from the prior year.
• Operating Income was -$11.4 million for Q1 2026 at Assembly Biosciences, down from $30.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $30.6 million in Q4 2025 to a low of -$24.6 million in Q2 2022.
• Historically, Operating Income has averaged -$12.8 million across 5 years, with a median of -$12.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Income dropped 23.98% in 2022, then soared 365.62% in 2025.
• A 5-year view of Operating Income shows it stood at -$23.0 million in 2022, then jumped by 45.38% to -$12.6 million in 2023, then increased by 8.12% to -$11.5 million in 2024, then jumped by 365.62% to $30.6 million in 2025, then plunged by 137.12% to -$11.4 million in 2026.
• The last three Operating Income figures came in at -$11.4 million (Q1 2026), $30.6 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.